The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss for the period | -102,411 | -118,605 | -115,915 | -1,057,431 |
| Loss on liability settlement | - | 1,603,193 | 0 | -801,193 |
| Accounts payable and accrued expenses | 8,249 | 1,127 | 243 | 1,630 |
| Accrued board of directors compensation | 101,250 | 105,750 | 104,551 | 211,500 |
| Net cash flows provided by (used in) operating activities | 7,088 | -10,921 | -11,121 | -43,108 |
| Proceeds from related parties | - | 10,923 | 11,000 | 43,151 |
| Capital contributions | - | - | - | 0 |
| Proceeds from (payments to) related parties | -1,527 | - | - | - |
| Net cash flows provided by (used in) financing activities | -1,527 | 10,923 | 11,000 | 43,151 |
| Cash flows from investing activities | - | - | - | 0 |
| Net change in cash | 5,561 | 2 | -121 | 43 |
| Cash - beginning of the period | 786 | 784 | 862 | - |
| Cash - end of the period | 6,347 | 786 | 784 | - |
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)